It is crucial that both effective vaccines and therapeutics become available to treat CV19. There is currently a very low bar set for effective therapeutics. We may hear as early as next week that Brilacidin trials for CV19 have been approved to proceed and possibly have started recruitment both internationally and in the U.S. We should get interim results in the next 60 days or less. If the B-CV19 human trial results resemble the excellent RBL testing, we will be part owners of the Gold Standard treatment for CV19 and many other diseases.
I am hopeful that there are one or more successful vaccines as well. We need both vaccines and therapeutics to significantly slow the CV19 pandemic. It is too early in the vaccine process to determine safety and overall efficacy as Drano and others have pointed out. The following article speaks volume to this as remarkably the AstraZeneca claim of 90% efficacy did not include patients over 55 years old.
====================
AstraZeneca’s 90% efficacy subgroup had an age cap of 55
The questions continue to pour in for AstraZeneca and Oxford’s Covid-19 vaccine candidate, after OWS chief Moncef Slaoui said Tuesday there was an age difference in the groups receiving the half-dose, then full-dose regimen and those getting two full-dose shots.
Patients in that half-then-full dose cohort, which showed the highest efficacy rate in the study at 90%, had an age cap of 55 years old, Business Insider reported. The full study had an average 70% efficacy, AstraZeneca said Monday, with patients who received two full doses clocking in at 62% efficacy.
Those numbers underwhelmed investors and analysts, as the Pfizer/BioNTech and Moderna mRNA vaccines both demonstrated 95% and 94.5% efficacy, the companies have respectively said. Jefferies’ Michael Yee summing up the sentiments: “We wonder which countries and populations would get the lower efficacy vaccine.”
AstraZeneca’s primary analysis was based on 11,636 volunteers from two trials conducted in the UK and Brazil. In total, there were 131 confirmed cases of Covid-19 — 30 in the vaccine group and 101 in the placebo arm.
Notably, the reason the half-full dosing regimen happened at all was due to a dosing error, per AstraZeneca’s R&D chief Mene Pangalos. Oxford researchers had begun administering the vaccine to volunteers before teaming up with the pharma company, and later “we found out that they had underpredicted the dose of the vaccine by half.” — Max Gelman
I am hopeful that there are one or more successful vaccines as well. We need both vaccines and therapeutics to significantly slow the CV19 pandemic. It is too early in the vaccine process to determine safety and overall efficacy as Drano and others have pointed out. The following article speaks volume to this as remarkably the AstraZeneca claim of 90% efficacy did not include patients over 55 years old.
====================
AstraZeneca’s 90% efficacy subgroup had an age cap of 55
The questions continue to pour in for AstraZeneca and Oxford’s Covid-19 vaccine candidate, after OWS chief Moncef Slaoui said Tuesday there was an age difference in the groups receiving the half-dose, then full-dose regimen and those getting two full-dose shots.
Patients in that half-then-full dose cohort, which showed the highest efficacy rate in the study at 90%, had an age cap of 55 years old, Business Insider reported. The full study had an average 70% efficacy, AstraZeneca said Monday, with patients who received two full doses clocking in at 62% efficacy.
Those numbers underwhelmed investors and analysts, as the Pfizer/BioNTech and Moderna mRNA vaccines both demonstrated 95% and 94.5% efficacy, the companies have respectively said. Jefferies’ Michael Yee summing up the sentiments: “We wonder which countries and populations would get the lower efficacy vaccine.”
AstraZeneca’s primary analysis was based on 11,636 volunteers from two trials conducted in the UK and Brazil. In total, there were 131 confirmed cases of Covid-19 — 30 in the vaccine group and 101 in the placebo arm.
Notably, the reason the half-full dosing regimen happened at all was due to a dosing error, per AstraZeneca’s R&D chief Mene Pangalos. Oxford researchers had begun administering the vaccine to volunteers before teaming up with the pharma company, and later “we found out that they had underpredicted the dose of the vaccine by half.” — Max Gelman
11
1
